bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo
Authors: Song Mengqiu , Liu Xuejiao , Liu Kangdong , Zhao Ran , Huang Hai , Shi Yuanyuan , Zhang Man , Zhou Silei , Xie Hua , Chen Hanyong , Li Yin , Zheng Yan , Wu Qiong , Liu Fangfang , Li Enmin , Bode Ann M. , Dong Zigang , Lee Mee-Hyun
Published: April 2023

Representative photographs of apoptosis after oridonin treatment in ESCC cells. Apoptosis was measured by flow cytometry in KYSE70, KYSE410 and KYSE450 cells after treatment with different concentrations of oridonin (0, 5, 10 or 20 μM).
Figure S2 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo
Authors: Song Mengqiu , Liu Xuejiao , Liu Kangdong , Zhao Ran , Huang Hai , Shi Yuanyuan , Zhang Man , Zhou Silei , Xie Hua , Chen Hanyong , Li Yin , Zheng Yan , Wu Qiong , Liu Fangfang , Li Enmin , Bode Ann M. , Dong Zigang , Lee Mee-Hyun
Published: April 2023

The cytotoxic effects of oridonin on normal SHEE esophageal cells were estimated by MTT assay at 24, 48 or 72 h and compared to DMSO control.
Supplementary Data from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Materials and Methods
Table S2 from A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway
Authors: Hsieh Chia-Ling , Huang Hsu-Shan , Chen Kuan-Chou , Saka Teigi , Chiang Chih-Ying , Chung Leland W.K. , Sung Shian-Ying
Published: April 2023

Biochemical parameters in the serum of mice before and after treatment with LCC03 (40 mg/kg) for 5 weeks.
Table S1 from A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway
Authors: Hsieh Chia-Ling , Huang Hsu-Shan , Chen Kuan-Chou , Saka Teigi , Chiang Chih-Ying , Chung Leland W.K. , Sung Shian-Ying
Published: April 2023

Information of antibodies used in this study
Supplementary Table S3 from MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Authors: Qu Jia-Quan , Yi Hong-Mei , Ye Xu , Zhu Jin-Feng , Yi Hong , Li Li-Na , Xiao Ta , Yuan Li , Li Jiao-Yang , Wang Yuan-Yuan , Feng Juan , He Qiu-Yan , Lu Shan-Shan , Xiao Zhi-Qiang
Published: April 2023

Microarray-based detection of differentially expressed miRNAs anticorrelated with mRNA expression in the CNE2-IR and CNE2 NPC cells
Figure S3 from A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway
Authors: Hsieh Chia-Ling , Huang Hsu-Shan , Chen Kuan-Chou , Saka Teigi , Chiang Chih-Ying , Chung Leland W.K. , Sung Shian-Ying
Published: April 2023

Effect of mTOR activation on LCC03-induced PERK expression
Figure S2 from A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway
Authors: Hsieh Chia-Ling , Huang Hsu-Shan , Chen Kuan-Chou , Saka Teigi , Chiang Chih-Ying , Chung Leland W.K. , Sung Shian-Ying
Published: April 2023

Effect of LCC03 on apoptosis of prostate cancer cells.
Supplementary Figure S3 from MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Authors: Qu Jia-Quan , Yi Hong-Mei , Ye Xu , Zhu Jin-Feng , Yi Hong , Li Li-Na , Xiao Ta , Yuan Li , Li Jiao-Yang , Wang Yuan-Yuan , Feng Juan , He Qiu-Yan , Lu Shan-Shan , Xiao Zhi-Qiang
Published: April 2023

Correlation analyses based on IHC scores and qRT-PCR 2-DDCt values (Spearman rank correlation test). The correlations shown include those between IL-8 and phospho-AKT (A), IL-8 and miR-203(B) and phospho-AKT and miR-203(C).
Supplementary Figures S1-S10 from Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis
Authors: Ramchandani Divya , Lee Seung Koo , Yomtoubian Shira , Han Myung Shin , Tung Ching-Hsuan , Mittal Vivek
Published: April 2023

Supplementary Figure S1. Cell cytotoxicity of NPs in MDA-MB-231 cells; Supplementary Figure S2. Localization of AuNP-cy5.5 in primary tumors; Supplementary Figure S3. Wound healing/Cell Migration Assay; Supplementary Figure S4. In vitro invasion after miR708-NP treatment; Supplementary Figure S5. Effect of miR-708 on Cell Proliferation; Supplementary Figure S6. Effect of miR-708 on Apoptosis; Supplementary Figure S7. Mammosphere formation in SORE6- versus SORE6+ cells; Supplementary Figure S8. Effect of AuNPs on myeloid population; Supplementary Figure S9. Effect of AuNPs on T-cells; Supplementary Figure S10. Effect of AuNPs on effector cytokines.
Supplementary Tables from Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Authors: Du Jian , Yan Lei , Torres Raquel , Gong Xueqian , Bian Huimin , Marugán Carlos , Boehnke Karsten , Baquero Carmen , Hui Yu-Hua , Chapman Sonya C. , Yang Yanzhu , Zeng Yi , Bogner Sarah M. , Foreman Robert T. , Capen Andrew , Donoho Gregory P. , Van Horn Robert D. , Barnard Darlene S. , Dempsey Jack A. , Beckmann Richard P. , Marshall Mark S. , Chio Li-Chun , Qian Yuewei , Webster Yue W. , Aggarwal Amit , Chu Shaoyou , Bhattachar Shobha , Stancato Louis F. , Dowless Michele S. , Iversen Phillip W. , Manro Jason R. , Walgren Jennie L. , Halstead Bartley W. , Dieter Matthew Z. , Martinez Ricardo , Bhagwat Shripad V. , Kreklau Emiko L. , Lallena Maria Jose , Ye Xiang S. , Patel Bharvin K.R. , Reinhard Christoph , Plowman Gregory D. , Barda David A. , Henry James R. , Buchanan Sean G. , Campbell Robert M.
Published: April 2023

Supplementary Tables
Supplementary Figure S2 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary Figure S2 shows binding of REGN3767 to T cells
Supplementary Figure 7 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
Authors: Rosas-Plaza Ximena , de Vries Gerda , Meersma Gert Jan , Suurmeijer Albert J.H. , Gietema Jourik A. , van Vugt Marcel A.T.M. , de Jong Steven
Published: April 2023

PDGFRbeta protein expression in TC cell lines
Supplementary Figure 3 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
Authors: Rosas-Plaza Ximena , de Vries Gerda , Meersma Gert Jan , Suurmeijer Albert J.H. , Gietema Jourik A. , van Vugt Marcel A.T.M. , de Jong Steven
Published: April 2023

mTOR knock down in combination with cisplatin in resistant TC cells
Supplementary Figure 2 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
Authors: Rosas-Plaza Ximena , de Vries Gerda , Meersma Gert Jan , Suurmeijer Albert J.H. , Gietema Jourik A. , van Vugt Marcel A.T.M. , de Jong Steven
Published: April 2023

Dasatinib in combination with cisplatin in resistant TC cells
Supplemental Figure and Table Legends and Tables S1-S2 from Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts
Authors: Chen Nancy E. , Maldonado N. Vanessa , Khankaldyyan Vazgen , Shimada Hiroyuki , Song Michael M. , Maurer Barry J. , Reynolds C. Patrick
Published: April 2023

Supplementary Table S1: Combination Index (CIN) for Fenretinide (4-HPR) and ABT-751 in Neuroblastoma Cell Lines at Each Concentration Tested; Supplementary Table S2: IC 90 and Combination Index (CIN) for Fenretinide and for Various Microtubule Inhibitors When Combined with Fenretinide in Neuroblastoma Cell Lines
Figure S6 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Authors: Zhou Sheng , Xu Huanji , Tang Qiulin , Xia Hongwei , Bi Feng
Published: April 2023

Model of the suppression of HMGCS1 to enhance the antitumour property of trametinib.
Figure S5 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Authors: Zhou Sheng , Xu Huanji , Tang Qiulin , Xia Hongwei , Bi Feng
Published: April 2023

Suppression of SREBF2 enhances the anti-tumour property of trametinib in CRC
Supplementary Figure S4 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Authors: Lopez Salvatore , Cocco Emiliano , Black Jonathan , Bellone Stefania , Bonazzoli Elena , Predolini Federica , Ferrari Francesca , Schwab Carlton L. , English Diana P. , Ratner Elena , Silasi Dan-Arin , Azodi Masoud , Schwartz Peter E. , Terranova Corrado , Angioli Roberto , Santin Alessandro D.
Published: April 2023

Variation in body weight of the mice treated with neratinib (40 mg\kg), taselisib (10 mg\kg) and the combination of the two inhibitors. The arrows denote the time point in which we started the combination treatment in single agent resistant mice (after 31 days and after 38 days for taselisib and neratinib group respectively for USPC-ARK-1 and after 25 days and after 45 days for USPC-ARK-2)
Supplementary Figure 3 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Authors: Chlenski Alexandre , Park Chanyoung , Dobratic Marija , Salwen Helen R. , Budke Brian , Park Jae-Hyun , Miller Ryan , Applebaum Mark A. , Wilkinson Emma , Nakamura Yusuke , Connell Philip P. , Cohn Susan L.
Published: April 2023

pRPA32 expression in neuroblastoma cells treated with OTS167 and CPT.
Supplementary Figure S2 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Authors: Lopez Salvatore , Cocco Emiliano , Black Jonathan , Bellone Stefania , Bonazzoli Elena , Predolini Federica , Ferrari Francesca , Schwab Carlton L. , English Diana P. , Ratner Elena , Silasi Dan-Arin , Azodi Masoud , Schwartz Peter E. , Terranova Corrado , Angioli Roberto , Santin Alessandro D.
Published: April 2023

Effect on pS6 in uterine serous carcinoma cells lines after exposure to neratinib, taselisib and the combination of both at the indicated concentration in a representative FISH+\PIK3CA mutated USC cell line (USPC-ARK-1) and in a representative FISH+\PIK3CA wild type USC cell line (USPC-ARK-2). A: Graph showing a statistically significant difference in the reduction of the mean fluorescence intensity (MFI) of pS6 in PIK3CA mutated/FISH+ cell line (USPC-ARK-1) after 24 hrs of treatment with taselisib, neratinib and the combination of both (*P=0.03, **P=0.03, ***P=0.0001). B: Graph showing a statistically significant difference in the reduction of the mean fluorescence intensity (MFI) of pS6 in PIK3CA wild type/FISH+ cell line (USPC-ARK-2) after 24 hrs of treatment with taselisib, neratinib and the combination of both (*P=0.01, **P=0.002).
Supplementary Figure 1 from Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Authors: Chlenski Alexandre , Park Chanyoung , Dobratic Marija , Salwen Helen R. , Budke Brian , Park Jae-Hyun , Miller Ryan , Applebaum Mark A. , Wilkinson Emma , Nakamura Yusuke , Connell Philip P. , Cohn Susan L.
Published: April 2023

MYCN/MYC expression in N-type and S-type neuroblastoma cell lines
Supplemental Table 4 from Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Authors: Li Guangmin , Guo Jun , Shen Ben-Quan , Yadav Daniela Bumbaca , Sliwkowski Mark X. , Crocker Lisa M. , Lacap Jennifer A. , Phillips Gail D. Lewis
Published: April 2023

Differentially expressed genes in T-DM1-resistant KPL-4 cells with respect to the parental cell line (fold change > 2-fold and P < 0.05 of individual probes for a given gene in the microarray)
Fig. S1 from Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
Authors: Singh Alok R. , Joshi Shweta , Burgoyne Adam M. , Sicklick Jason K. , Ikeda Sadakatsu , Kono Yuko , Garlich Joseph R. , Morales Guillermo A. , Durden Donald L.
Published: April 2023

Annexin-V FITC analysis of SF1126 and Sorafenib treated HCC cells
Supplemental Table 1 from Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Authors: Li Guangmin , Guo Jun , Shen Ben-Quan , Yadav Daniela Bumbaca , Sliwkowski Mark X. , Crocker Lisa M. , Lacap Jennifer A. , Phillips Gail D. Lewis
Published: April 2023

BT-474M1 TR vs. Parental cells, gene expression changes >5-fold
Supplemental Figures and Legends from Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Authors: Li Guangmin , Guo Jun , Shen Ben-Quan , Yadav Daniela Bumbaca , Sliwkowski Mark X. , Crocker Lisa M. , Lacap Jennifer A. , Phillips Gail D. Lewis
Published: April 2023

Supplemental Figure 1. Upregulated BHLHE41 in KPL-4 TR and BT-474M1 TR cells does not confer resistance to T-DM1. Supplemental Figure 2. Flow cytometry analysis of HER2 and MDR1 expression in KPL-4 P and TR cells, and tumor derived KPL-4 TR cells. Supplemental Figure 3. qRT-PCR analysis of ErbB receptors and ligands in KPL-4 and BT-474M1 P and TR cells. Supplemental Figure 4. Flow cytometry analysis of HER2 expression in BT-474M1 P and TR cells. Supplemental Figure 5. Immunofluorescence detection of cell surface HER2 on BT-474M1 and T-DM1 resistant cells. Supplemental Figure 6. Analysis of T-DM1 uptake in BT-474M1 P and TR, and KPL-4 P and TR cells using radiolabeled T-DM1. Supplemental Figure 7. Treatment of KPL-4 TR cells with anti-IGF-1R antibody 10H5 or the selective c-met inhibitor PHA665725 does not restore sensitivity to T-DM1. Supplemental Figure 8. Upregulated EGFR does not mediate resistance to T-DM1 in KPL-4 TR cells. Supplemental Figure 9. Potential autocrine receptor-ligand interactions for T-DM1 resistance. Supplemental Figure 10. Comparable shRNA knockdown of PTEN in BT-474M1 cells in 2 different shRNA clones, #1 and #3. Supplemental Figure 11. Molecular alterations in BT-474M1 TR cells that did not confer T-DM1 resistance. Supplemental Figure 12. Expression of drug resistance transporters, assessed by qRT-PCR, in KPL-4 and BT-474M1 parental and TR cells. Supplemental Figure 13. The MDR1 inhibitor XR9051 and the BCRP inhibitor Ko143 do not affect cell viability Supplemental Figure 14. MRP4 siRNA in BT-474M1 TR does not reverse T-DM1 resistance. Supplemental Figure 15. MRP4 siRNA in KPL-4 TR does not reverse T-DM1 resistance. Supplemental Figure 16. Expression of SLC46A3 in KPL-4 parental and TR cells assessed by qRT-PCR. Supplemental Figure 17. SLC46A3 siRNA in BT-474M1 TR cells significantly reverses T-DM1 resistance.
Supplementary Figure S2 from Serum- and Glucocorticoid-inducible Kinase 1 is Essential for Osteoclastogenesis and Promotes Breast Cancer Bone Metastasis
Authors: Zhang Zheng , Xu Qian , Song Chao , Mi Baoguo , Zhang Honghua , Kang Honglei , Liu Huiyong , Sun Yunlong , Wang Jia , Lei Zhuowei , Guan Hanfeng , Li Feng
Published: April 2023

Quantification for Western Blot and Schematic representation
Supplementary Figure S1 from Serum- and Glucocorticoid-inducible Kinase 1 is Essential for Osteoclastogenesis and Promotes Breast Cancer Bone Metastasis
Authors: Zhang Zheng , Xu Qian , Song Chao , Mi Baoguo , Zhang Honghua , Kang Honglei , Liu Huiyong , Sun Yunlong , Wang Jia , Lei Zhuowei , Guan Hanfeng , Li Feng
Published: April 2023

Assay in cell line
Supplementary Figure 1 from Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
Authors: Flem-Karlsen Karine , McFadden Erin , Omar Nasrin , Haugen Mads H. , Øy Geir Frode , Ryder Truls , Gullestad Hans Petter , Hermann Robert , Mælandsmo Gunhild Mari , Flørenes Vivi Ann
Published: April 2023

Supplementary Figure 1 shows AXL expression in a melanoma cell line panel, dose response of BGB324 and how BGB324 treatment affects invasion and migration.
Supplementary Table 2 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Authors: Restelli Valentina , Lupi Monica , Chilà Rosaria , Vagni Micaela , Tarantelli Chiara , Spriano Filippo , Gaudio Eugenio , Bertoni Francesco , Damia Giovanna , Carrassa Laura
Published: April 2023

GSEA of transcripts upregulated in cells with high sensitivity (responders) to AZD6738.
Supplementary Table 1 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Authors: Restelli Valentina , Lupi Monica , Chilà Rosaria , Vagni Micaela , Tarantelli Chiara , Spriano Filippo , Gaudio Eugenio , Bertoni Francesco , Damia Giovanna , Carrassa Laura
Published: April 2023

Primers used for real-time PCR on cDNA
Supplementary Figures 1-8 from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Authors: Restelli Valentina , Lupi Monica , Chilà Rosaria , Vagni Micaela , Tarantelli Chiara , Spriano Filippo , Gaudio Eugenio , Bertoni Francesco , Damia Giovanna , Carrassa Laura
Published: April 2023

Supplementary Figure 1. Correlation analysis among the different drug IC50s; Supplementary Figure 2. AZD6738 IC50 in all the 36 B-cell lymphoma cells and their molecular characteristics; Supplementary Figure 3: Cell cycle and DNA damage protein levels in the different cell lines under study; Supplementary Figure 4: Correlation between drug IC50s and biomarkers of response; Supplementary Figure 5: Cell cycle perturbation induced by single and combined treatments with the inhibitors; Supplementary Figure 6: Biparametric analysis of pS10-Histone H3 and DNA in OCILY-7 cells untreated or 8, 24 and 48 h after treatment with the drug either singly or combined. Caspase-3 activity assay 8, 24 and 48h after treatment with the three drugs either singly or combined Real time PCR showing Myc, Wee1 and RRM2 expression levels after 24 and 48h of treatment with the drugs either singly or combined; Supplementary Figure 7: Body weights of mice transplanted with OCILY-7 xonografts treated or not with the single agents and with the combination. Tumor growth curves in OCILY-7 xenograft transplanted mice untreated or treated at a late stage; Supplementary Figure 8: Antitumor activity and pharmacodimamic markers of single and combined agents in JEKO1 xenografts
Supplementary Data from Inhibition of Y Box Binding Protein 1 Suppresses Cell Growth and Motility in Colorectal Cancer
Authors: Kim Areumnuri , Shim Sehwan , Kim Young-heon , Kim Min-Jung , Park Sunhoo , Myung Jae Kyung
Published: April 2023

We cited references containing drug structure and included source of drugs
Table S3 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

List of genes from the DEG clustering analysis.
Supplementary Figures from Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies
Authors: Lu Haihui , Molony Ryan D. , Chen Dongshu , Jang Sunyoung , Wolf Babette , Ewert Stefan , Flaherty Meghan , Xu Fangmin , Isim Sinan , Shim Yeonju , Dornelas Christina , Balke Nicole , Leber Xavier Charles , Scharenberg Meike , Koelln Johanna , Choi Eugene , Ward Rebecca , Johnson Jennifer , Calzascia Thomas , Isnardi Isabelle , Williams Juliet A. , Lindenbergh Pieter L. , van de Donk Niels W.C.J. , Mutis Tuna , Huet Heather , Lees Emma , Meyer Matthew J.
Published: April 2023

Supplementary Figures S1-S9 show CD32b mRNA vs protein expression, preclinical activity of NVS32b1 vs NVS32b2, differential activation of human vs mouse FcgRs, CD32b expression on cell lines and healthy immune cells.
Table S1 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

LogFC and p-value of differentially gene expression between untreated, early, and late treatment samples for each PDX model.
Figure S6 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

Three drug combination of BRAF, MEK, and ERK inhibitors is well-tolerated in vivo.
Supplementary Data from Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia
Authors: Chan Wai-Kin , Horvath Thomas D. , Tan Lin , Link Todd , Harutyunyan Karine G. , Pontikos Michael A. , Anishkin Andriy , Du Di , Martin Leona A. , Yin Eric , Rempe Susan B. , Sukharev Sergei , Konopleva Marina , Weinstein John N. , Lorenzi Philip L.
Published: April 2023

Supplementary Figures and Tables
COI Form_Karine from Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia
Authors: Chan Wai-Kin , Horvath Thomas D. , Tan Lin , Link Todd , Harutyunyan Karine G. , Pontikos Michael A. , Anishkin Andriy , Du Di , Martin Leona A. , Yin Eric , Rempe Susan B. , Sukharev Sergei , Konopleva Marina , Weinstein John N. , Lorenzi Philip L.
Published: April 2023

COI Form_Karine from Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia
Figure S3 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

Overlap between in vivo and in vitro derived melanoma gene signatures
Figure S2 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

Overlap in differentially expressed genes upon MAPK inhibition among PDX models
Supplemental Figure 1-3 from Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors
Authors: Seol Yeonee , Zhang Hongliang , Agama Keli , Lorence Nicholas , Pommier Yves , Neuman Keir C.
Published: April 2023

Supplemental information contains three figures. Figure s1 displays plots of in vitro inhibition plotted versus IC50 values for inhibitors as measured for three individual cell lines. Figure S2 displays the low rate probability and religation inhibition measures of inhibition plotted versus the average normalized IC50 values for each of the four inhibitors. Figure S3 displays the fraction of relaxed DNA measured in the ensembled supercoil relaxation assay as a function of the inhibitor concentration for the four inhibitors.
Supplementary Table 1 from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Authors: Sasikumar Pottayil G. , Ramachandra Raghuveer K. , Adurthi Srinivas , Dhudashiya Amit A. , Vadlamani Sureshkumar , Vemula Koteswararao , Vunnum Sriharibabu , Satyam Leena K. , Samiulla Dodderi S. , Subbarao Krishnaprasad , Nair Rashmi , Shrimali Rajeev , Gowda Nagaraj , Ramachandra Murali
Published: April 2023

Table 1A: Rescue of proliferation and IFN- γ release in the presence of PD-L1 or PD-L2 in mouse splenocytes Table 1B: Rescue of proliferation and IFN- γ release in the presence of PD-L1 or PD-L2 in human PBMCs
Supplementary Figure 5 Pharmacokinetic profile of NP-12 from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Authors: Sasikumar Pottayil G. , Ramachandra Raghuveer K. , Adurthi Srinivas , Dhudashiya Amit A. , Vadlamani Sureshkumar , Vemula Koteswararao , Vunnum Sriharibabu , Satyam Leena K. , Samiulla Dodderi S. , Subbarao Krishnaprasad , Nair Rashmi , Shrimali Rajeev , Gowda Nagaraj , Ramachandra Murali
Published: April 2023

Supplementary Figure 5 Pharmacokinetic profile of NP-12
Figure S4 from Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression
Authors: Hafeez Bilal Bin , Ganju Aditya , Sikander Mohammed , Kashyap Vivek K. , Hafeez Zubair Bin , Chauhan Neeraj , Malik Shabnam , Massey Andrew E. , Tripathi Manish K. , Halaweish Fathi T. , Zafar Nadeem , Singh Man M. , Yallapu Murali M. , Chauhan Subhash C. , Jaggi Meena
Published: April 2023

Effect of ORM on cell cycle analysis and β-catenin localization. A. Histogram (i) and table (ii) represent the cell cycle distribution in DU145 cells. B. Confocal images of β-catenin, DAPI and merged images of control (i) and ORM treated (ii) PC3 cells.
Supplementary Figure 2 Elevated production of IFN-γ by NP-12 in Staphylococcus Enterotoxin B (SEB) stimulated human PBMCs from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Authors: Sasikumar Pottayil G. , Ramachandra Raghuveer K. , Adurthi Srinivas , Dhudashiya Amit A. , Vadlamani Sureshkumar , Vemula Koteswararao , Vunnum Sriharibabu , Satyam Leena K. , Samiulla Dodderi S. , Subbarao Krishnaprasad , Nair Rashmi , Shrimali Rajeev , Gowda Nagaraj , Ramachandra Murali
Published: April 2023

Supplementary Figure 2 Elevated production of IFN-γ by NP-12 in Staphylococcus Enterotoxin B (SEB) stimulated human PBMCs
Figure S2 from Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression
Authors: Hafeez Bilal Bin , Ganju Aditya , Sikander Mohammed , Kashyap Vivek K. , Hafeez Zubair Bin , Chauhan Neeraj , Malik Shabnam , Massey Andrew E. , Tripathi Manish K. , Halaweish Fathi T. , Zafar Nadeem , Singh Man M. , Yallapu Murali M. , Chauhan Subhash C. , Jaggi Meena
Published: April 2023

Effect of ORM on colonigenic and invasive potential of C4-2 cells: A. Effect of ORM on proliferation of C4-2 cells as determined by colony formation assay. B. Effect of ORM anchorage-independent growth of C4-2 cells as determined by soft agar colony Formation. Representative images showing colony formation in control and ORM treated groups. Bar graph indicates number of colony formed in control and ORM treated groups. Values represent mean {plus minus}SE of 3 plates. C. Effect of ORM on invasion of C4-2 cells as determined by Boyden chamber assay. i) Representative images showing invaded cells in control and ORM treated groups after 24 hrs. ii) Bar graph indicating average number of invaded cells in control and ORM treated groups.
Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
Authors: Wengner Antje M. , Siemeister Gerhard , Lücking Ulrich , Lefranc Julien , Wortmann Lars , Lienau Philip , Bader Benjamin , Bömer Ulf , Moosmayer Dieter , Eberspächer Uwe , Golfier Sven , Schatz Christoph A. , Baumgart Simon J. , Haendler Bernard , Lejeune Pascale , Schlicker Andreas , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Tables S1-S4
Table S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
Authors: Manara Maria Cristina , Valente Sergio , Cristalli Camilla , Nicoletti Giordano , Landuzzi Lorena , Zwergel Clemens , Mazzone Roberta , Stazi Giulia , Arimondo Paola B. , Pasello Michela , Guerzoni Clara , Picci Piero , Nanni Patrizia , Lollini Pier-Luigi , Mai Antonello , Scotlandi Katia
Published: April 2023

Inhibitory activity of MC3343 against human DNMT1 and human DNMT3a
Supplementary Tables from Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers
Authors: Arora Arvind , Parvathaneni Swetha , Aleskandarany Mohammed A. , Agarwal Devika , Ali Reem , Abdel-Fatah Tarek , Green Andrew R. , Ball Graham R. , Rakha Emad A. , Ellis Ian O. , Sharma Sudha , Madhusudan Srinivasan
Published: April 2023

Supplementary Table S1: Clinicopathological characteristics in the METABRIC cohort Supplementary Table S2: Clinicopathological characteristics of Nottingham Tenovus series Supplemental Table S3: Clinicopathological characteristics of ER- cohort Supplemental Table S4: Clinicopathological characteristics of BRCA germ-line deficient cohort Supplementary Table S5: Antigens, primary antibodies, clone, source, optimal dilution and scoring system used for each immunohistochemical marker Supplementary Table S6. RecQL1 mRNA expression and breast cancer. Supplementary Table S7. RECQL1 protein levels and ER+ breast cancers. Supplementary Table S8. RECQL1 protein levels and ER- breast cancers.
Supplementary Figure legends from Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers
Authors: Arora Arvind , Parvathaneni Swetha , Aleskandarany Mohammed A. , Agarwal Devika , Ali Reem , Abdel-Fatah Tarek , Green Andrew R. , Ball Graham R. , Rakha Emad A. , Ellis Ian O. , Sharma Sudha , Madhusudan Srinivasan
Published: April 2023

Supplementary Figure S1. RECQL1 and survival in ER+ or ER- breast cancer patients. Supplementary Figure S2. RECQL1-depleted MCF-7 cells exhibit sensitivity to doxorubicin. Supplementary Figure S3. RECQL1 depletion and ERα protein levels.
Supplementary figure 4 from TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Authors: Rodríguez-Ruiz María E. , Rodríguez Inmaculada , Mayorga Lina , Labiano Tania , Barbes Benigno , Etxeberria Iñaki , Ponz-Sarvise Mariano , Azpilikueta Arantza , Bolaños Elixabet , Sanmamed Miguel F. , Berraondo Pedro , Calvo Felipe A. , Barcelos-Hoff Mary Helen , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Myeloid cell content (density per gram) in cell suspension from non-irradiated tumors as those in figure 5. Macrophages are defined as CD45+ CD11b+ F4/80+; Dendritic cells (DC) as CD45+CD11b+CD11c+; myeloid-derived suppressor cells (MDSC) as CD45+CD11b+Ly6C+ or CD45+CD11b+Ly6G+ to estimate monocytic (M-MDSC) and granulocytic (G-MDSC) subtypes.
Supplementary Table S2 from Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia
Authors: Papaioannou Dimitrios , Nicolet Deedra , Ozer Hatice G. , Mrózek Krzysztof , Volinia Stefano , Fadda Paolo , Carroll Andrew J. , Kohlschmidt Jessica , Kolitz Jonathan E. , Wang Eunice S. , Stone Richard M. , Byrd John C. , Garzon Ramiro , Bloomfield Clara D.
Published: April 2023

Supplementary Table S2, provided as a separate Excel file. Contains a list of custom designed probes for expression profiling of prognostic long non-coding RNAs with the nCounter assay
Supplementary figure 2 from TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Authors: Rodríguez-Ruiz María E. , Rodríguez Inmaculada , Mayorga Lina , Labiano Tania , Barbes Benigno , Etxeberria Iñaki , Ponz-Sarvise Mariano , Azpilikueta Arantza , Bolaños Elixabet , Sanmamed Miguel F. , Berraondo Pedro , Calvo Felipe A. , Barcelos-Hoff Mary Helen , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

: Experimental treatments (A) and tumor size follow-up until sacrifice (B) of tumors used to prepare cell suspensions for figures 3, 5 and supplementary figure 4. (C) Shows individual tumor lesion weights used to calculate lymphocytes/gram densities.
Figure S6 from Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Authors: Tang Xiaoyun , Wuest Melinda , Benesch Matthew G.K. , Dufour Jennifer , Zhao YuanYuan , Curtis Jonathan M. , Monjardet Alain , Heckmann Bertrand , Murray David , Wuest Frank , Brindley David N.
Published: April 2023

Protein levels of cytokines in tumors with or without irradiation and/or GLPG1690. n = 5 in control, n = 6 in other groups. * P<0.05, ** P<0.01, ***P<0.001.
Figure S4 from Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Authors: Tang Xiaoyun , Wuest Melinda , Benesch Matthew G.K. , Dufour Jennifer , Zhao YuanYuan , Curtis Jonathan M. , Monjardet Alain , Heckmann Bertrand , Murray David , Wuest Frank , Brindley David N.
Published: April 2023

Immunohistochemistry staining for ATX and Bcl-2 in mouse breast tumor and tumor-adjacent adipose. A: ATX staining in tumors. B: ATX staining in tumor-adjacent adipose. C: Bcl-2 staining in tumors. Scale bar = 100 mm.
Figure S1 from Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma
Authors: Xie Xiaoling , Chen Yiran , Hu Yuxing , He Yanjie , Zhang Honghao , Li Yuhua
Published: April 2023

Representative flow cytometry data showed that RPMI 8226 and MM1.S were negative for the expression of HLA-A*0201, U266 and ARH-77 were positive for the expression of HLA-A*0201.
Figure S2 from Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Authors: Tang Xiaoyun , Wuest Melinda , Benesch Matthew G.K. , Dufour Jennifer , Zhao YuanYuan , Curtis Jonathan M. , Monjardet Alain , Heckmann Bertrand , Murray David , Wuest Frank , Brindley David N.
Published: April 2023

Immunohistochemistry images for Ki67. A: Ki67 staining in tumors treated with GLPG1690 in combination with RT. B: Ki67 staining in tumors treated with GLPG1690 in combination with doxorubicin. Scale bar = 100 mm.
Supplementary figures 1-6 from Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Authors: Nisa Lluís , Francica Paola , Giger Roland , Medo Matúš , Elicin Olgun , Friese-Hamim Manja , Wilm Claudia , Stroh Christopher , Bojaxhiu Beat , Quintin Aurélie , Caversaccio Marco D. , Dettmer Matthias S. , Buchwalder Mélanie , Brodie Tess M. , Aebersold Daniel M. , Zimmer Yitzhak , Carey Thomas E. , Medová Michaela
Published: April 2023

Supplementary figure 1 provides data concerning establishment of organotypic tissue cultures from freshly-resected HNSCC specimen Supplementary figure 2 shows analyses of MET expression and mutational status in a HNSCC cohort Supplementary figure 3 shows impact of MET inhibition by tepotinib in HNSCC cell lines in vitro Supplementary figure 4 shows effects of combined treatment by tepotinib and ionizing radiation on HNSCC cell lines Supplementary figure 5 shows analyses of OTCs responses to treatment by tepotinib combined with ionizing radiation Supplementary figure 6 shows results of assays studying mechanisms underlying tepotinib-mediated radiosensitization of HNSCC cell lines
Supplemental Table 1-3 from CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Authors: Xiang Jingyu , Hurchla Michelle A. , Fontana Francesca , Su Xinming , Amend Sarah R. , Esser Alison K. , Douglas Garry J. , Mudalagiriyappa Chidananda , Luker Kathryn E. , Pluard Timothy , Ademuyiwa Foluso O. , Romagnoli Barbara , Tuffin Gérald , Chevalier Eric , Luker Gary D. , Bauer Michael , Zimmermann Johann , Aft Rebecca L. , Dembowsky Klaus , Weilbaecher Katherine N.
Published: April 2023

Supplemental Table 1-3. Pharmacology of POL5551 and patient characteristics at baseline
Supplementary Table 1 from Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Authors: Nisa Lluís , Francica Paola , Giger Roland , Medo Matúš , Elicin Olgun , Friese-Hamim Manja , Wilm Claudia , Stroh Christopher , Bojaxhiu Beat , Quintin Aurélie , Caversaccio Marco D. , Dettmer Matthias S. , Buchwalder Mélanie , Brodie Tess M. , Aebersold Daniel M. , Zimmer Yitzhak , Carey Thomas E. , Medová Michaela
Published: April 2023

Supplementary Table 1 shows HNSCC patients' characteristics
Table S2 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

Antibody information
Table S1 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

Information of drug library
Supplementary Materials and Methods from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

Supplementary information
Supplementary Table S3 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Summary of antitumor activity of LY3214996 and other MAPK pathway inhibitors in cancer models with dominant MAPK pathway alterations
Supplementary Table S2 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Abs IC50 of LY3214996 and ERK pathway alterations in 60 cancer cell lines profiled for antitumor activity in cell proliferation assay
Supplementary Table S1 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Biochemical and cellular selectivity profile of LY3214996 (DiscoveRx and ActiveX data)
Figure S3 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

Specificity of anti-MAP2 antibody in mouse primary cortical neuron culture
Supplementary Methods from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Supplementary Methods
Figure S2 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

The image-based high-content screening platform
Figure S1 from Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy
Authors: Chen Li-Hsien , Sun Yuan-Ting , Chen Yih-Fung , Lee Mei-Yi , Chang Lian-Yun , Chang Jang-Yang , Shen Meng-Ru
Published: April 2023

Flow chart for drug discovery
Supplementary Figure S6 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Generation of vemurafenib-resistant A375 model in vivo.
Supplementary Figure S8 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Authors: Stremitzer Stefan , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Matsusaka Satoshi , Parekh Anish , Okazaki Satoshi , Hanna Diana , Astrow Stephanie H. , Moran Miriana , Hernandez Jose , Stephens Craig , Scherer Stefan J. , Stift Judith , Wrba Friedrich , Gruenberger Thomas , Lenz Heinz-Josef
Published: April 2023

Kaplan Meier curves for VEGFB mRNA levels in CLM for OS (complete response, CR; standard error, SE)
Supplementary Tables S1-S3; Supplementary Figures S1-S3; and Supplementary Materials and Methods from Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
Authors: Tanaka Hiroaki , Sakagami Hideki , Kaneko Naoki , Konagai Satoshi , Yamamoto Hiroko , Matsuya Takahiro , Yuri Masatoshi , Yamanaka Yosuke , Mori Masamichi , Takeuchi Masahiro , Koshio Hiroyuki , Hirano Masaaki , Kuromitsu Sadao
Published: April 2023

Supplementary Table S1 shows inhibitory effect of naquotinib against wild type or mutant EGFR kinase activity. Supplementary Table S2 shows inhibitory effect of naquotinib on the proliferation of Ba/F3 cells overexpressing mutant EGFRs. Supplementary Table S3 shows inhibitory effect of naquotinib against AXL kinase activity. Supplementary Figure S1 shows chemical structures of naquotinib, osimertinib, rociletinib and olmutinib. Supplementary Figure S2 shows that covalent binding between naquotinib and the Cys-797 residue of EGFR L858R/T790M was confirmed by LC-MS/MS analysis Supplementary Figure S3 shows that naquotinib did not affect the body weight of mice in the HCC827, NCI-H1975 or A431 xenograft models Supplementary Materials and Methods are as follows; 1. Generation of Ba/F3 cells expressing mutant EGFRs 2. Generation of PC-9AXL cells 3. Mass spectrometry analysis of the position of the covalent bond between naquotinib and EGFR L858R/T790M 4. Measurement of EGFR phosphorylation in NCI-H1975 tumors 5. Antibodies 6. In vitro cell proliferation assays
Supplementary Figure S7 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Authors: Stremitzer Stefan , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Matsusaka Satoshi , Parekh Anish , Okazaki Satoshi , Hanna Diana , Astrow Stephanie H. , Moran Miriana , Hernandez Jose , Stephens Craig , Scherer Stefan J. , Stift Judith , Wrba Friedrich , Gruenberger Thomas , Lenz Heinz-Josef
Published: April 2023

Kaplan Meier curves for ACVRL1 mRNA levels in CLM for OS (complete response, CR; standard error, SE)
Supplementary Figure S5 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Authors: Stremitzer Stefan , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Matsusaka Satoshi , Parekh Anish , Okazaki Satoshi , Hanna Diana , Astrow Stephanie H. , Moran Miriana , Hernandez Jose , Stephens Craig , Scherer Stefan J. , Stift Judith , Wrba Friedrich , Gruenberger Thomas , Lenz Heinz-Josef
Published: April 2023

Kaplan Meier curves for EGFL7 mRNA levels in CLM for RFS (complete response, CR)
Supplementary Figure S4 from Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection
Authors: Stremitzer Stefan , Zhang Wu , Yang Dongyun , Ning Yan , Sunakawa Yu , Matsusaka Satoshi , Parekh Anish , Okazaki Satoshi , Hanna Diana , Astrow Stephanie H. , Moran Miriana , Hernandez Jose , Stephens Craig , Scherer Stefan J. , Stift Judith , Wrba Friedrich , Gruenberger Thomas , Lenz Heinz-Josef
Published: April 2023

Kaplan Meier curves for KDR mRNA levels in CLM for RFS (complete response, CR)
Supplementary Table 2 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Compounds used in the high throughput drug screen in the panel of OCCC cell lines
Supplementary figure legends from Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Authors: Meerang Mayura , Bérard Karima , Felley-Bosco Emanuela , Lauk Olivia , Vrugt Bart , Boss Andreas , Kenkel David , Broggini-Tenzer Angela , Stahel Rolf A. , Arni Stephan , Weder Walter , Opitz Isabelle
Published: April 2023

Supplementary figure legends